These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 24652679)
81. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. Schapansky J; Nardozzi JD; LaVoie MJ Neuroscience; 2015 Aug; 302():74-88. PubMed ID: 25284317 [TBL] [Abstract][Full Text] [Related]
82. Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis. Cabezudo D; Tsafaras G; Van Acker E; Van den Haute C; Baekelandt V Acta Neuropathol; 2023 Aug; 146(2):245-261. PubMed ID: 37289222 [TBL] [Abstract][Full Text] [Related]
83. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252 [TBL] [Abstract][Full Text] [Related]
84. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. Herzig MC; Bidinosti M; Schweizer T; Hafner T; Stemmelen C; Weiss A; Danner S; Vidotto N; Stauffer D; Barske C; Mayer F; Schmid P; Rovelli G; van der Putten PH; Shimshek DR PLoS One; 2012; 7(5):e36581. PubMed ID: 22615783 [TBL] [Abstract][Full Text] [Related]
85. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006 [TBL] [Abstract][Full Text] [Related]
87. Sleep aspects on video-polysomnography in LRRK2 mutation carriers. Ehrminger M; Leu-Semenescu S; Cormier F; Corvol JC; Vidailhet M; Debellemaniere E; Brice A; Arnulf I Mov Disord; 2015 Nov; 30(13):1839-43. PubMed ID: 26468079 [TBL] [Abstract][Full Text] [Related]
88. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? Loeffler DA; Aasly JO; LeWitt PA; Coffey MP J Parkinsons Dis; 2019; 9(3):467-488. PubMed ID: 31322581 [TBL] [Abstract][Full Text] [Related]
89. The synaptic function of LRRK2. Lee S; Imai Y; Gehrke S; Liu S; Lu B Biochem Soc Trans; 2012 Oct; 40(5):1047-51. PubMed ID: 22988863 [TBL] [Abstract][Full Text] [Related]
91. Non-motor and motor features in LRRK2 transgenic mice. Bichler Z; Lim HC; Zeng L; Tan EK PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174 [TBL] [Abstract][Full Text] [Related]
92. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642 [TBL] [Abstract][Full Text] [Related]
94. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models. Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314 [TBL] [Abstract][Full Text] [Related]
95. Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Su YC; Guo X; Qi X Biochim Biophys Acta; 2015 Jan; 1852(1):12-21. PubMed ID: 25446991 [TBL] [Abstract][Full Text] [Related]
96. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2 Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932 [TBL] [Abstract][Full Text] [Related]
97. LRRK2 signaling pathways: the key to unlocking neurodegeneration? Berwick DC; Harvey K Trends Cell Biol; 2011 May; 21(5):257-65. PubMed ID: 21306901 [TBL] [Abstract][Full Text] [Related]